Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
Brachytherapy “is the treatment of choice” for men with penile carcinoma whose cancer has not spread to the corpus cavernosum.
The use of the radioguided sentinel lymph node biopsy (rSLNB) technique may lead to management change in more than 33% of patients with papillary thyroid cancer.
Regorafenib provides a statistically significant benefit for non-liposarcoma patients with pre-treated, metastatic sarcoma.
Talimogene laherparepvec (T-VEC), an oncolytic virus, in conjunction with ipilimumab, an immune checkpoint inhibitor, may be more beneficial than either agent alone for patients with advanced melanoma.
Tasquinimod improved radiographic progression-free survival (rPFS) in contrast with placebo in chemotherapy-naïve men with mCRPC.
Adjuvant chemotherapy with S-1 may improve standard of care for Japanese patients with resected pancreatic cancer.
Addition of olaratumab to doxorubicin significantly improves PFS and OS in patients with advanced soft-tissue sarcoma.
A study of twins with 22 980 individuals suggested that the familial risk for testicular cancer may be dramatically underestimated.
Human leukocyte antigen (HLA) expression appears to be tied to clinical outcomes in penile cancer.
Please login or register first to view this content.